The contribution of Fc-mediated effector functions to the therapeutic efficacy of some monoclonal antibodies has motivated efforts to enhance interactions with Fc; receptors (Fc;R). Although an early goal has been enhanced Fc;RIIIa binding and natural killer (NK) cell antibody-dependent cell-mediated cytotoxicity (ADCC), other relevant cell types such as macrophages are dependent on additional activating receptors such as Fc;RIIa. Here, we describe a set of engineered Fc variants with diverse Fc;R affinities, including a novel substitution G236A that provides selectively enhanced binding to Fc;RIIa relative to Fc;RIIb. Variants containing this substitution have up to 70-fold greater Fc;RIIa affinity and 15-fold improvement in Fc;RIIa/Fc;RIIb ratio and mediate enhanced phagocytosis of antibody-coated target cells by macrophages. Specific double and triple combination variants with this substitution are simultaneously capable of exhibiting high NK-mediated ADCC and high macrophage phagocytosis. In addition, we have used this unique set of variants to quantitatively probe the relative contributions of individual Fc;R to effector functions mediated by NK cells and macrophages. These experiments show that Fc;RIIa plays the most influential role for macrophages and, surprisingly, that the inhibitory receptor Fc;RIIb has little effect on effector function. The enhancements in phagocytosis described here provide the potential to improve the performance of therapeutic antibodies targeting cancers.
Introduction
It is well documented that the activating Fcg receptor (FcgR) FcgRIIIa plays an important role in the therapeutic activity of some monoclonal antibodies. Its clinical relevance is supported by the correlations observed between human FcgRIIIa polymorphism and response to therapy with the anti-CD20 antibody rituximab (Rituxan; refs. 1 -4) . These results are consistent with demonstrations in mouse models that FcgR are critical to antibody anticancer activity (5 -7) . Motivated by this work, several studies have used amino acid engineering (8 -10) and glycoengineering (11, 12) to enhance the interactions between the antibody Fc region and FcgRIIIa. Amino acid variants or glycoform modifications have been generated that provide up to 100-fold greater affinity for FcgRIIIa compared with native IgG1, resulting in up to 100-fold improvements in ADCC. The amino acid variants tend to have broader affinity enhancements for multiple FcgR, whereas glycoform perturbations that generate afucosylated antibodies lead to FcgRIIIa-specific affinity improvement. Engineered antibodies using both technologies are currently under development (13) .
The role of FcgRIIa in the efficacies of IgG1-derived antibodies, although more speculative, is important to explore for several reasons. First, R131 FcgRIIa is associated with greater susceptibility to infectious disease, a relationship that is hypothesized to be due to the critical role of IgG2 in fighting pathogens and the capacity of this isotype to mediate monocyte and neutrophil effector function only with the H131 form (14 -16) . Second, neuroblastoma patients homozygous for R131 FcgRIIa had significantly improved progression-free survival when treated with an anti-GD2 murine IgG3 antibody, which has a strong affinity preference for the R131 form of FcgRIIa. Finally, murine FcgRIV, whose expression on murine effector cells parallels that of human FcgRIIa, plays a dominant role in the in vivo efficacy of anti-CD20 antibodies in mouse models (6, 7) .
In contrast to the activating receptors, FcgRIIb elicits negative intracellular signals that down-regulate immune cell function. The therapeutic relevance of FcgRIIb is supported by the improved antibody antitumor activity (5) and greater B-cell depletion (7) observed in FcgRIIb -/-mice, and the correlation observed between the anticancer activity of mouse IgG subclasses and their activating to inhibitory (A/I) ratios (17) . These results have led to the hypothesis that A/I ratios are an important variable in determining antibody-mediated effector function (17) . Overall, the current view is that the antibody effector functions of monocytes, macrophages, and dendritic cells are governed by the interplay among FcgRIIa, FcgRIIIa, and FcgRIIb (17 -20) .
Efforts to improve antibodies by engineering selective binding to FcgRIIa and FcgRIIIa relative to FcgRIIb have met with marginal success. The difficulty is no doubt due to the high homology of the receptors, particularly between FcgRIIa and FcgRIIb, which share 93% sequence identity in their extracellular domains and are very similar at the Fc binding interface. We now describe a panel of human antibody Fc variants with a variety of unique FcgR affinities and specificities, including selective engagement of FcgRIIIa and FcgRIIa relative to FcgRIIb. The enhancements in macrophage phagocytosis mediated by these novel variants show that Fc engineering could be used to increase the activity of effector cell types expressing both activating and inhibitory receptors. These variant provide the potential to improve the performance of monoclonal antibodies targeting cancers and infectious diseases and have enabled us to probe the roles of the different FcgR in the effector functions of different immune cell types.
Materials and Methods

Construction and Production of FcVariant Antibodies
The variable region for the humanized anti-epithelial cell adhesion molecule (EpCAM) antibody is an engineered version of sequences that were generated previously (21) . Variable region genes were ligated into the vector pcDNA3.1Zeo (Invitrogen) containing the human light chain n and heavy chain constant regions. Fc mutations were introduced into the heavy chain using QuickChange mutagenesis techniques (Stratagene). All DNA was confirmed by sequencing. Light and heavy chain plasmids were cotransfected into 293T cells and antibodies were purified using protein A chromatography (Pierce). Antibody and receptor concentrations were determined by bicinchoninic acid assay (Pierce).
Receptors, Antibodies, and Cell Lines Human Fc receptors with His tags were obtained from R&D Systems (FcgRI and FcgRIIb) or constructed internally (R131 and H131 FcgRIIa and V158 and F158 FcgRIIIa). Biacore experiments measuring antibody binding to internally expressed R131 FcgRIIa and the same receptor purchased commercially gave identical affinities (data not shown), indicating consistency between the two sources. Blocking antibodies for ADCC and phagocytosis studies, including anti-FcgRI (clone 10.1), anti-FcgRII (clone AT10), and antiFcgRIII (clone 3G8), were purchased from GeneTex, AbD Serotec, and BD Biosciences, respectively. Anti-FcgRIIbspecific antibody 2B6 (22) was constructed by gene synthesis, subcloned into pcDNA3.1Zeo as a His-tagged chimeric F(ab), and a full-length chimeric antibody. 2B6 antibodies were expressed in 293T cells and purified using nickel affinity or protein A chromatography. Full-length 2B6 was labeled with Percp (Prozyme) according to the manufacturer's instructions. Allophycocyanin (APC) -labeled anti-CD11b, APC-labeled anti-CD14, PE-labeled anti-CD66, and PECyan7-labeled anti-FcgRIII (clone 3G8) were purchased from BD Biosciences. FITC-labeled anti-FcgRII (clone IV.3) and PElabeled anti-FcgRI (clone 10.1) were purchased from Stem Cell Technologies and eBioscience, respectively. Control IgG used in cell-based assays was a human IgG1 targeting respiratory syncytial virus, the variable region of which was made by gene synthesis. The LS180 cell line was obtained from the American Type Culture Collection.
Determination of Fc Receptor Binding Affinities Surface plasmon resonance measurements were done using a Biacore 3000 instrument. Antibodies were captured onto an immobilized protein A/G (Pierce) CM5 biosensor chip (Biacore) generated using standard primary amine coupling. All measurements were done in HBS-EP (Biacore), and glycine buffer (Biacore) was used for surface regeneration. Antibodies (50 nmol/L in HBS-EP) were immobilized on the protein A/G surface for 5 min at 1 AL/min. Fc receptors in 2-fold serial dilutions (starting at 1 or 2 Amol/L, six concentrations total) were injected over antibody bound surface for 2 min at 20 AL/min followed by a 2 or 3 min dissociation phase. After each cycle, the surface was regenerated with glycine buffer. Data were processed by zeroing time and response before the injection of receptor and by subtracting from a reference channel to account for changes due to injections. To correct for baseline drift due to any dissociation of IgG, all experiments were preceded with injection of buffer alone after IgG binding, which was then subtracted from all traces as background as a part of data-processing step termed ''double referencing'' (23) . Kinetic data were fit to a 1:1 binding model (Langmuir) using the BIAevaluation software. Binding curves of the six FcgR concentration series were fitted individually. Kinetic variables were used to calculate the equilibrium dissociation constant (K d ) and SD.
ADCC Assays ADCC was measured by lactate dehydrogenase release using the Cytotox-ONE Homogeneous Membrane Integrity Assay (Promega). Human peripheral blood mononuclear cells (PBMC) were purified from leukopacks using a Ficoll gradient. DNA genotyping for FcgRIIa (position 131) and FcgRIIIa (position 158) was carried out using methods by and as a commercial service at Gentris Clinical Genetics. EpCAM + LS180 target cells were seeded into 96-well plates at 20,000 per well and opsonized using antibodies at the indicated concentrations. Triton X-100 and PBMC alone were run as controls. Effector cells were added at 25:1 PBMC/target cells, and plates were incubated at 37jC, 5% CO 2 for 4 h. Cells were then incubated with lactate dehydrogenase reaction mixture for 10 min, and fluorescence was measured using a Wallac Victor2 fluorometer (Perkin-Elmer). All ADCC reactions were done in triplicate. Fluorescence due to spontaneous PBMC and target cell lysis (without antibodies) was subtracted from experimental values (with antibodies), normalized to maximal (Triton) and minimal (no Triton) lysis, and fit to a sigmoidal dose-response. For FcgR blocking studies, 10 Ag/mL murine IgG control, anti-FcgRII, or anti-FcgRIII and a single concentration of opsonizing antibodies (0.316 Ag/mL) were incubated with the target cells for 45 min before the addition of effector cells.
Macrophage Cultures, Phenotype, and Fc;R Quantitation CD14 + cells were purified from PBMC by EasySep Human Monocyte Enrichment Kit without CD16 depletion (Stem Cell Technologies). Purified CD14 + monocytes were cultured in macrophage colony-stimulating factor (Peprotech) at 50 ng/mL for 5 days in a humidified incubator. Differentiated macrophages were identified by combination of anti-CD11b-APC and anti-CD14-APC and phenotyped for the expression of FcgRI, FcgRIIa, FcgRIIb, and FcgRIII by multiplexed flow cytometry. Briefly, a 1:50 dilution of antibodies that identified the above receptors was incubated on ice for 30 min and washed twice with PBS. Receptor quantification was done using either the Quantum Simply Cellular Mouse Antibody-Binding Standards or the Human Antibody-Binding Standards (Bangs Laboratories) according to the manufacturer's instructions. Briefly, macrophages were dual stained with the combination of anti-CD11b-APC and anti-CD14-APC with either anti-FcgRI-PE, anti-FcgRIIa-FITC, anti-FcgRIIbPercp, or anti-FcgRIII-PE-Cyan7. The same concentration of antibody that was used to stain FcgR on the macrophages was incubated with the beads. The bead fluorescence intensity was then used as a standard curve to determine the number of receptors on the cells (24) .
Phagocytosis Assays
Macrophage antibody-dependent cell-mediated phagocytosis (ADCP) was determined by flow cytometry. Target LS180 cells were labeled with PKH67 (Sigma) and seeded at 25,000 per well into 96-well plates in the presence of 10% human AB serum. Antibodies were diluted serially to 8 half-log concentrations and added to the target cells. Monocyte-derived macrophages were then added at 4:1 effector:target. Cells were spun down briefly and incubated at 37jC for 4 h. Cells were detached from the plate surface with HyQtase, stained with anti-CD11b-APC, anti-CD14-APC, and anti-CD66-PE, washed with PBS, and fixed with 1% paraformaldehyde. Phagocytosis was evaluated on a FACSCanto II flow cytometer (BD Biosciences), and percent phagocytosis was calculated as the number of double-positive cells divided by the total number of tumor cells. The intensity of CD66 staining was used to determine the degree to which tumor cells were internalized. For FcgR blocking experiments, 10 Ag/mL anti-FcgRI, antiFcgRII, anti-FcgRIIb, anti-FcgRIII, control murine IgG, or control human F(ab) were added to the macrophages before the addition of target cells and opsonizing antibodies (0.316 Ag/mL).
Results
Engineered Fc Variants Have Diverse and Selective Fc;R Affinity Profiles
We have described previously the engineering of antibody Fc variants for improved FcgRIIIa affinity (9) . Characterization of two point variants, S239D and I332E, and the corresponding double variant S239D/I332E showed that they provide greater FcgRIIIa affinity and enhanced effector function in vitro and in vivo relative to native IgG1. Subsequently, we screened a larger set of >900 variants for binding to all FcgR, including FcgRI, FcgRIIa, FcgRIIb, and FcgRIIIa. 1 Among the most intriguing receptor affinity profiles from this screen were variants with greater affinity for FcgRIIa relative to the inhibitory receptor FcgRIIb. A single mutation, G236A, was identified that fit this target profile. This mutation was combined with I332E and S239D/I332E to generate additional variants I332E/G236A and S239D/I332E/ G236A. Variants were constructed in the context of fulllength antibodies containing the variable region of a humanized anti-EpCAM antibody (21) , expressed in 293T cells, and purified.
Binding affinities of the variant antibodies to all human FcgR relevant to monocytic cells were determined using Biacore. Figure 1A shows example sensorgrams for binding of native IgG1 and G236A variant antibodies to the R131 form of FcgRIIa. The G236A variant exhibits a marked enhancement in response unit intensity and a slower off-rate relative to native IgG1. Fits of the data for all the variants provided equilibrium K d values and fold affinities relative to native IgG1 (Table 1 ). Figure 1B shows a plot of the affinities on a logarithmic scale for binding of each antibody to each receptor. The values obtained for native IgG1 agree well with published data (see footnotes for Table 1 ). The 4-fold ratio of affinities for binding of native IgG1 to the two FcgRIIIa alleles (V/F158) is also consistent with the literature as is the equivalent affinity of IgG1 for the H131 and R131 alleles of FcgRIIa (contrasting with the well-known H131 preference of IgG2; ref. 25) .
The Biacore data indicate that the G236A mutation provides a 6-to 7-fold enhancement in binding to both isoforms of FcgRIIa but does not alter affinity for the inhibitory receptor FcgRIIb or FcgRIIIa ( Fig. 1B ; Table 1 ). However, it reduces FcgRI affinity f7-fold. Addition of this mutation to I332E and S239D/I332E imparts its unique profile to these variants-binding of I332E/G236A and S239D/I332E/G236A to FcgRIIa, and the ratios of FcgRIIa to FcgRIIb affinities are enhanced relative to the single and double variants, respectively. Addition of G236A again reduces binding to the other activating receptors, although affinity of I332E/G236A and S239D/I332E/G236A for FcgRI remains comparable with or greater than native IgG1, and FcgRIIIa binding is still dramatically improved (6-and 31-fold for binding to the more prevalent F158 isoform by the double and triple variants, respectively). Overall, the variants provide a spectrum of diverse FcgR affinity profiles.
With respect to utility for improving effector function, the reduced affinity to FcgRI potentially makes the single substitution variant G236A suboptimal in spite of its enhanced affinity for FcgRIIa. The I332E variant provides nearly selective enhancement to FcgRIIIa, with a possible slight increase in affinity for the other receptors. I332E/ G236A has an almost ideal Fc receptor profile for enhancing effector function-up to a log greater affinity for all isoforms of FcgRIIa and FcgRIIIa, improved FcgRIIa/FcgRIIb and FcgRIIIa/FcgRIIb ratios, and unaltered affinity to FcgRI. The S239D/I332E double variant has greater improvements to FcgRIIIa relative to I332E and alone has enhanced binding to both FcgRIIa isoforms. A theoretical drawback is that it also binds more tightly to FcgRIIb. Addition of G236A, although not affecting the absolute FcgRIIb affinity, dramatically improves its FcgRIIa/FcgRIIb ratio while still leaving it with a very high FcgRIIIa affinity relative to native IgG1.
As an additional comparator, we generated an afucosylated [fuc(-)] version of the IgG1 anti-EpCAM antibody. Removal of fucose from the complex carbohydrate attached at N297 improves binding only to FcgRIIIa (26, 27) . This profile is consistent with a model for enhancement involving alleviation of a steric interaction between Fc fucose and carbohydrate on the receptor (26), a mechanism that should only enhance affinity to human FcgRIIIa/b due to lack of an asparagine at the analogous position in the other receptors. We produced fuc(-) antibody by expressing the native IgG1 anti-EpCAM in the Lec13 CHO line (28) . Antibodies expressed in this cell line are consistently f90% fuc(-) in contrast to normal CHO lines that produce f2% fuc(-) antibody (29) . Biacore data showed that fuc(-) enhanced affinity only for FcgRIIIa (Fig. 1B) , consistent with results from other studies (26, 27) and the receptor glycosylation model (26) . FcgRIIIa affinity enhancements for fuc(-) antibody were 16-and 10-fold for the V158 and F158 alleles, respectively (Table 1) .
Fc Variants with Increased Affinity for Fc;RIIIa Enhance ADCC Mediated by Natural Killer Cells
Variant antibodies were evaluated for their capacity to mediate ADCC activity using PBMC as effector cells. Target cells were EpCAM + LS180, a colon adenocarcinoma cell line. PBMC were allotyped for V/F158 FcgRIIIa and H/ R131 FcgRIIa polymorphism, and lysis was measured using release of lactate dehydrogenase. Improvements in both EC 50 and maximal lysis relative to native IgG1 were observed for all the variants except G236A, which showed a reduction in ADCC activity ( Fig. 2A) . Similarly, the addition of G236A to I332E reduced maximal activity relative to the single I332E variant, although it maintained improved potency relative to native IgG1. In contrast, the S239D/I332E/G236A variant showed only a modest decline relative to the double variant potentially due to their much higher FcgRIIIa affinities (Table 1) . Similar results were observed when the ADCC assay was carried out with PBMC from donors having the low responder R/ R131 FcgRIIa and F/F158 FcgRIIIa genotype (data not shown).
A general trend was observed for a dependence of ADCC activity on FcgRIIIa affinity. To explore this more quantitatively, the negative log of the EC 50 for each variant was plotted versus the log of its corresponding association constant (K a ) for each of the receptors. A strong correlation was observed between ADCC activity and affinity for FcgRIIIa (r 2 = 0.93 and 0.97 for V158 and F158, respectively; Fig. 2B ), despite the fact that binding assays measured monomeric IgG, whereas ADCC assays assessed activity of opsonized cells with enhanced avidity for low affinity FcgR. The relationship with FcgRIIIa was distinctly stronger than correlations with the other activating receptors (r 2 = 0.34-0.57; data not shown). To corroborate these results, we used blocking antibodies to selectively inhibit FcgRII or FcgRIII. Whereas an antibody that blocks both FcgRIIa and FcgRIIb had no effect on ADCC activity, blocking FcgRIII dramatically inhibited ADCC by the variants and native IgG1 (Fig. 2C) . As an additional confirmation of the importance of FcgRIIIa, we determined ADCC for fuc(-) antibody and compared the results with those obtained for the I332E/G236A and S239D/I332E double variants. Enhancements in activity were observed by both the variants and fuc(-) antibody (Fig. 2D) , with the rank order of improvement consistent with their FcgRIIIa affinity.
The strong dependence on FcgRIIIa suggests that ADCC activity by PBMC is dominated by natural killer (NK) cells, which express only this receptor among the FcgR [with few exceptions (30) ]. To directly determine the role of NK cells in mediating ADCC, we tested our antibodies using PBMC depleted of NK cells. Consistent with previous studies (31, 32) , ADCC activity was abolished for native IgG1 as well as the variants tested (data not shown). Taken together, the data confirm that under the conditions of this assay ADCC activity by PBMC is mediated primarily by FcgRIIIa on NK cells. Table 1 .
Fc Variants with Increased Fc;RIIa Affinity Enhance ADCC by Macrophages
To evaluate the FcgR dependence for a cell type with a more complex receptor expression profile, we investigated the capacity of the Fc variant antibodies to promote phagocytosis by macrophages. Monocytes were purified from PBMC and differentiated into macrophages using macrophage colony-stimulating factor, confirmed by the expression of CD14 and CD11b. Multivariant flow cytometry was used to determine FcgR expression levels. As seen in Fig. 3A , the macrophage phenotype consisted of FcgRIIa, FcgRIIb, FcgRIII, and low levels of FcgRI. Bead-based quantification was used to obtain an approximate receptor number (24) . Consistent with the distribution in the cytometry profiles, FcgRIIa had the highest level of expression followed by FcgRIIb, FcgRIII, and FcgRI (Fig. 3B) .
To evaluate phagocytosis, PKH67-labeled LS180 target cells were opsonized with the various anti-EpCAM antibodies and incubated with macrophages. Macrophages were stained with anti-CD14-APC and anti-CD11b-APC, and LS180 tumor cells were stained with anti-CD66-PE. With this triple staining method, macrophages that phagocytose tumors should be double positive for PKH67 and CD11b/CD14. Target cells that are internalized should also be less intensely stained for CD66 compared with residual tumor cells. As shown in Fig. 3C , native IgG1 significantly increased phagocytosis compared with controls, and activity was enhanced even further by the S239D/I332E variant.
To compare the potencies of the various Fc-modified antibodies, phagocytosis was measured as a function of antibody concentration for each of the variants using H/ H131 FcgRIIa and V/F158 FcgRIIIa macrophages (Fig. 4A) . Substantial improvements in both half-maximal effective concentration (EC 50 ) and maximal phagocytosis relative to native IgG1 were observed for all the variants. The I332E variant showed modest improvement followed by S239D/ I332E. The FcgRIIa-selective G236A variant provided substantial improvements to activity by itself. Its combination with the other two variants led to further enhancements, with the triple mutant showing the highest activity. Improvements by fuc(-) antibody were comparable with those of I332E, consistent with their similar FcgR profiles. Repeat experiments using different donors consistently resulted in enhancements, although the degree of improvements varied from donor to donor. Greater enhancements were observed using macrophages possessing the R/R131 FcgRIIa and F/F158 FcgRIIIa genotype (Fig. 4B ) due in part to the poor activity of native IgG1 with this donor. Further experiments are required to evaluate the significance of allelic differences on macrophage activity.
To quantify the relative importance of the individual FcgR in macrophage ADCC, we plotted the log of the affinities (K a ) against the negative log of the EC 50 values for each of the receptors (Fig. 4C) . In contrast to the ADCC analysis, the strongest correlation was seen with FcgRIIa (r 2 = 0.79 and 0.80), and poor correlations were seen with FcgRI (r 2 = 0.00) and FcgRIIIa (r 2 = 0.09 and 
Blocking Antibodies Confirm Fc-Engineered Targeting of Fc;RIIa and Show Its Importance in Macrophage Phagocytosis
To confirm the importance of FcgRIIa in macrophagemediated ADCC, specific FcgR blocking antibodies were included in the assay before addition of tumor cells and antibodies. For native IgG1 and all variants, simultaneous blocking of FcgRIIa and FcgRIIb had the greatest inhibitory effect on phagocytosis (Fig. 5A ) with H/H131 V/F158 macrophages. Inhibition of FcgRII was most dramatic with G236A. Modest inhibition was observed when FcgRI or FcgRIIIa were blocked, indicating that these activating receptors also contribute. Their role is most apparent by the dramatic reduction in phagocytosis observed when all three of the activating FcgR are simultaneously blocked. Investigation of the role of FcgRIIb was enabled by an antibody (2B6) selective for this receptor, the specificity of which has been shown in the literature (22) and confirmed in our own work (data not shown). Blocking FcgRIIb alone had little or no effect (Fig. 5A) on phagocytosis mediated by any of the variants. These blocking experiments indicate a dominant role for FcgRIIa in mediating macrophage phagocytosis, relatively lower contributions from FcgRI and FcgRIII, and minimal effect from FcgRIIb. Isolation of phagocytosis to single receptors, carried out by combining blocking antibodies, confirmed these results, particularly the importance of FcgRIIa for variants containing the G236A mutation (Supplementary Fig. S1 ). 
Fc;RIIb Does Not Suppress Macrophage Phagocytosis
FcgRIIb has been reported to inhibit macrophage phagocytosis by modulating the threshold of activation (19) . However, as discussed above, our variant series showed no systematic relationship between affinity for FcgRIIb and phagocytic potency, nor did we observe an effect on phagocytosis when FcgRIIb was selectively blocked. However, in these studies the controls for all but one of the variants already exhibited nearly maximal phagocytosis, making it difficult to observe any further enhancement with inhibitory receptor blockade. We therefore repeated the FcgRIIb blocking experiments with macrophages from the same H/H131 V/F158 donor using a lower concentration of the antibodies. Consistent with the prior study, FcgRIIb blockade again had no effect (Fig. 5B) . Similar results were observed with macrophages from donors having the low responder R/R131 F/F158 genotype ( Supplementary Fig. S1 ). 2 
Discussion
Modification of antibodies to optimize FcgR affinities, such as described here and in previous work (8 -12) , has become a promising strategy for improving their therapeutic activity. Despite significant progress, however, the ideal profile(s) of FcgR affinities and selectivities remain undefined. Accordingly, we continue to engineer additional 2 Supplementary material for this article is available at Molecular Cancer Therapeutics Online (http://mct.aacrjournals.org/). FcgR selectivities through amino acid substitution and use the variants to further define the precise FcgR binding profiles for optimal activity of the relevant immune cells. Our specific goals for this study were 2-fold. First, we set out to engineer and evaluate the benefit of variants with selective affinity enhancement for FcgRIIIa and FcgRIIa relative to FcgRIIb. Second, we wished to characterize at a detailed affinity level the contribution of individual receptors to the effector functions of cells with both simple (NK cells) and complex (macrophages) FcgR expression. NK cells are unique among effector cells in that they typically express only the activating receptor FcgRIIIa and are not subject to inhibition by FcgRIIb. When PBMC were used as effectors, lysis was mediated almost completely by the NK cell population, shown by the strong correlation with FcgRIIIa affinity, the substantial reduction in activity when blocked with anti-FcgRIII but not anti-FcgRII antibodies, and the complete lack of activity upon NK cell depletion. The optimal receptor profile for NK-mediated ADCC is clearly greater affinity for FcgRIIIa. Overall, the work here on NK cells, a simple system with respect to Fc receptors, gave no surprises and served more as a control for our approach to studying effector functions using the Fc variants. Moreover, the absolute dependence of these standard ADCC assays on NK cells cautions against extrapolating relative variant activities into clinical settings where multiple effector cells and cytotoxic mechanisms are involved. ) for all data, the -G236A subset, and the +G236A subset as well as the P values for the significance between the subsets and all data.
Macrophages are a more complex cell type with respect to Fc receptor expression. They express various levels of all the activating and inhibitory FcgR subject to regulation by cytokines. Studies on the FcgR dependence of human macrophage phagocytosis have shown that qualitatively both FcgRIIa and FcgRIIIa can mediate phagocytosis of antibody-coated cells but that FcgRIIIa expression is more heterogeneous (18, 33, 34) . In our studies, macrophages cultured in macrophage colony-stimulating factor expressed high levels of FcgRIIa, lower but still significant levels of FcgRIIb and FcgRIIIa, and low levels of FcgRI. The most important finding was that antibody variants with improved FcgRIIa affinity, contributed most markedly by the G236A mutation, enhanced macrophage-mediated phagocytosis relative to native IgG1. The importance of FcgRIIa was supported by the strong correlation observed between its affinity and phagocytosis and confirmed by the prominent reductions in activity observed when it was blocked using anti-FcgRII antibody. The effect of blocking FcgRII was most significant for native IgG1 and variants with high affinity for FcgRIIa, the most dramatic of which was G236A. However, the effect of anti-FcgRII was also observed for I332E and S239D/I332E, two variants that improve affinity to FcgRIIIa more than FcgRIIa. Together with the slight but consistent reductions in phagocytosis observed when FcgRI and FcgRIIIa were blocked, the data suggest that these receptors play a complimentary role to FcgRIIa. Indeed, nearly perfect correlations between phagocytosis EC 50 and FcgRIIIa affinity were observed when variants were separated into high (+G236A) and low (-G236A) FcgRIIa affinity subsets. This analysis is not conclusive due to the minimal number of points. Nonetheless, this relationship suggests that FcgRIIa is a coarse knob for macrophage phagocytosis, setting the maximal level of activity that is tuned more finely by FcgRIIIa.
In contrast to the activating receptors, FcgRIIb played a minimal role in regulating tumor cell phagocytosis. Even variants with increased binding to FcgRIIb showed enhanced ADCC, and a negative correlation was not observed between FcgRIIb affinity and ADCC activity. These data suggest that biasing affinity toward activating receptors is sufficient for increased phagocytic activity. This result is in striking contrast to the growing paradigm that FcgRIIb modulates the activation threshold for cells Figure 5 . FcgRIIa dominates macrophage phagocytosis. A, use of selective blocking antibodies confirms the importance of FcgRIIa. ADCC was determined as described in Fig. 4 , except selective FcgR blocking antibodies were added to the macrophages at 10 Ag/mL before the addition of tumor cells and 0.316 Ag/mL opsonizing antibodies. Gray, controls containing no antibody (all -) or nonspecific murine IgG (Cntrl + ); black, samples with blocking antibodies. For native IgG1 and all variants, blocking both FcgRIIa and FcgRIIb (a-II + ) had the greatest inhibitory effect, especially for the FcgRIIa-selective G236A variant. In contrast, blocking FcgRIIb alone (a-IIb +) had no effect. Some inhibition was seen with individual FcgRI (a-I + ) or FcgRIII (a-III +) blockade, and the most dramatic reduction was seen with simultaneous blockade of all three activating FcgR, indicating a dominant role for FcgRIIa and contributing roles for FcgRI and FcgRIII. B, FcgRIIb plays a minimal role. Blocking studies with anti-FcgRIIb were repeated using a lower concentration of opsonizing antibodies (0.10 Ag/mL) so that any enhancement due to inhibitory receptor blockade could more readily be observed. Although phagocytosis was below maximal for all controls, FcgRIIb blockade again had no effect. Gray, controls containing no antibody (all -) or nonspecific human F(ab) (Cntrl + ). FcgRIIa and FcgRIIIa genotypes for both experiments (A and B) were H/H131 and V/F158, respectively. These results are representative of at least two independent experiments. (19, 35) . In these studies, however, there was no simultaneous evaluation of the effect on activating receptors, and more recent work has shown that interleukin-4 reduces their expression (36) . The in vivo role of FcgRIIb is supported by the greater antibody antitumor activity and increased B-cell depletion observed in FcgRIIb -/-mice (5, 7). The reason(s) for the disconnect between these studies and the results for human macrophages observed in our work is not clear, although it is worth emphasizing that the enhanced activities observed in the FcgRIIb -/-mice were generally observed at subtherapeutic doses of antibody. Overall, the results may indicate that the qualitative roles of the different FcgR determined from perturbations such as heterologous expression, blocking, and knockout studies do not directly define the optimal Fc receptor affinity profile(s) for a given cell type.
In the context of antitumor therapy, many questions remain as to the importance of NK cells relative to other FcgR-bearing effector cells despite their prominent reputation for mediating ADCC. Although they are the simplest link between the clinical correlations observed between FcgRIIIa polymorphism and outcome in anti-CD20 therapy, macrophages and dendritic cells also express FcgRIIIa. The relevance of macrophages and dendritic cells to antibody antitumor mechanism has been implicated by the observed capacity of macrophages and dendritic cells to infiltrate tumors (37, 38) , the monocyte dependence of antibodymediated efficacy in mouse studies (6, 7) , and the growing evidence that antibody therapy can induce an adaptive immune response (39, 40) . For example, mice deficient of tissue macrophages were found to be more resistant to antibody-mediated B-cell depletion (6) . Furthermore, specific mouse IgG isotypes and engineered antibodies with increased binding to FcgRIV, present on murine monocytes and neutrophils but not NK cells, have shown enhanced B-cell depletion, and blocking FcgRIV greatly diminishes this activity (10) .
In human therapy, the improved survival observed for neuroblastoma patients having the higher-affinity allele of FcgRIIa (R131 for mouse IgG3) would seem to support a role for myeloid lineage cells in efficacy (41) at least for some indications. Although such correlations have also been observed in non-Hodgkin's lymphoma and breast cancer for rituximab and trastuzumab, respectively (3, 42) , a recent study suggests that these correlations are due to linkage disequilibrium between FcgRIIa and FcgRIIIa (43), consistent with the lack of affinity preference of IgG1 for either FcgRIIa allele. Additional myeloid cells include neutrophils and dendritic cells, both of which express FcgRIIa. We are currently evaluating the capacity of the variants described here to improve neutrophil ADCC, which is known to be strongly dependent on FcgRIIa (44) . Dendritic cells, likewise, have been shown to be dependent on FcgRIIa for immunocomplex-stimulated maturation (45) , an important factor in cross-presentation of tumorderived antigens and activation of antitumor cytotoxic T lymphocytes (20) . A major goal for the field of therapeutic antibodies is to converge Fc engineering capabilities with clear definitions of both the optimal FcgR profile(s) for different effector cells and the relevance of each cell type to the treatment of a particular cancer.
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